Department of Pediatrics, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
PLoS One. 2020 Aug 28;15(8):e0238185. doi: 10.1371/journal.pone.0238185. eCollection 2020.
Recent studies have reported that after the introduction of rotavirus vaccine the incidence of intussusception did not change among infants, or slightly increased at the age immediately after the first dose. The rotavirus vaccines were introduced in Korea for private market use in 2007-2008. We investigated the incidence of intussusception before (2002-2006) and after (2009-2015) the vaccine introduction in Korea.
We conducted an interrupted time series study that used data from the Korean National Health Insurance database to identify infants (<12 months of age) who were diagnosed with intussusception and underwent non-invasive or invasive reduction from 2002 to 2015. According to the recommended ages for immunization, the annual intussusception incidence and the incidence rate ratios were calculated among three age groups, 6-14, 15-24, and 25-34 weeks.
The annual incidences in infants have decreased over time from 241.7 per 100,000 infants (pre-vaccine period) to 160.1-205.2 per 100,000 infants (post-vaccine period). The incidence rate ratio during the post-vaccine period ranged from 0.66 to 0.85. The incidences of intussusception in all three infant age groups have decreased in post-vaccine period compared to pre-vaccine period (incidence rate ratio range: 0.31-0.65, 0.47-0.75, and 0.68-0.94 in 6-14, 15-24, and 25-34 weeks, respectively).
The incidence of intussusception in infants did not increase after the rotavirus vaccine introduction in Korea, but rather decreased over the past decades. Since the incidence of intussusception varies according to country or region, continuous monitoring the incidence of intussusception in infants is necessary in each county or region.
最近的研究报告称，轮状病毒疫苗问世后，婴儿的肠套叠发病率并未改变，或者在第一针后立即增加。轮状病毒疫苗于 2007-2008 年在韩国为私人市场使用而推出。我们调查了韩国在疫苗推出前后（2002-2006 年和 2009-2015 年）肠套叠的发病率。
我们进行了一项中断时间序列研究，使用韩国国家健康保险数据库的数据来确定 2002 年至 2015 年期间被诊断为肠套叠并接受非侵入性或侵入性复位的婴儿（<12 个月大）。根据免疫接种推荐年龄，计算了三个年龄组（6-14 周、15-24 周和 25-34 周）的年度肠套叠发病率和发病率比值。
婴儿的年发病率随着时间的推移从疫苗接种前的 241.7/100,000 婴儿下降到疫苗接种后的 160.1-205.2/100,000 婴儿。疫苗接种后期间的发病率比值范围为 0.66 至 0.85。与疫苗接种前相比，所有三个婴儿年龄组的肠套叠发病率在疫苗接种后均有所下降（发病率比值范围：6-14 周为 0.31-0.65，15-24 周为 0.47-0.75，25-34 周为 0.68-0.94）。
轮状病毒疫苗在韩国推出后，婴儿肠套叠的发病率并未增加，而是在过去几十年中有所下降。由于肠套叠的发病率因国家或地区而异，因此有必要在每个国家或地区持续监测婴儿的肠套叠发病率。
